You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020113013
Dec 20203009
Jan 2021802
Feb 2021802
Mar 20213004
Apr 20213605
May 2021402
Jun 2021004
Jul 2021003
Aug 2021004
Sep 2021003
Oct 20218020
Nov 20214016
Dec 20211000
Jan 2022600
Feb 2022802
Mar 20221000
Apr 20222600
May 202250012
Jun 20221600
Jul 2022601
Aug 20221204
Sep 20221200
Oct 2022600
Nov 20221201
Dec 20221401
Jan 20231001
Feb 20231800
Mar 2023800
Apr 20231801
May 2023200
Jun 2023400
Jul 2023402
Aug 20231002
Sep 2023601
Oct 20232005
Nov 20231001
Dec 20231801
Jan 2024400
Feb 20241400
Mar 20242201
Apr 2024800
May 20241000
Jun 20242800
Jul 2024800
Aug 20241801
Sep 2024602
Oct 20241402
Nov 2024601
Dec 2024601
Jan 2025405
Feb 2025001
Mar 2025009
Apr 2025003
May 2025002
Jun 2025003
Total7050153